pemvidutide — Topline data
H2 2027
The Company expects to report topline data in the second half of 2027Source filing
ALT biotech catalysts & pipeline
ALTIMMUNE INC · Data as of 2026-09-08
Upcoming catalysts
pemvidutide — Topline data
2029
In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029Source filing